Cargando…

Secondary Progressive Multiple Sclerosis: New Insights

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, espe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cree, Bruce A.C., Arnold, Douglas L., Chataway, Jeremy, Chitnis, Tanuja, Fox, Robert J., Pozo Ramajo, Angela, Murphy, Niamh, Lassmann, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397587/ https://www.ncbi.nlm.nih.gov/pubmed/34088878 http://dx.doi.org/10.1212/WNL.0000000000012323

Ejemplares similares

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis
por: Lewin, Alex, et al.
Publicado: (2016)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Neurofilaments in progressive multiple sclerosis: a systematic review
por: Williams, Thomas, et al.
Publicado: (2020)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial
por: Cree, Bruce A.C., et al.
Publicado: (2018)

Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
por: Chan, Dennis, et al.
Publicado: (2017)

Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
por: Vesterinen, Hanna M., et al.
Publicado: (2015)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
por: Williams, Thomas, et al.
Publicado: (2022)

Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes
por: Chitnis, Tanuja, et al.
Publicado: (2022)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Mitochondrial defects in acute multiple sclerosis lesions
por: Mahad, Don, et al.
Publicado: (2008)

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
por: Connick, Peter, et al.
Publicado: (2018)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Experience with long-term rituximab use in a multiple sclerosis clinic
por: Barra, Megan E, et al.
Publicado: (2016)

The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids
por: Rakusa, Martin, et al.
Publicado: (2023)

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
por: Cohen, Jeffrey A, et al.
Publicado: (2022)

The Role of Autoimmunity in Multiple Sclerosis
por: Bradl, Monika, et al.
Publicado: (2005)

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis
por: Jia, Xiaoming, et al.
Publicado: (2018)

Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020)

How patients with multiple sclerosis acquire disability
por: Lublin, Fred D, et al.
Publicado: (2022)

Multiple sclerosis: experimental models and reality
por: Lassmann, Hans, et al.
Publicado: (2016)

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
por: Lassmann, Hans
Publicado: (2019)

Hypoxia-like tissue injury as a component of multiple sclerosis lesions
por: Lassmann, Hans
Publicado: (2003)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study
por: Marshall, Ian, et al.
Publicado: (2018)

Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset
por: Bove, Riley, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_90t15gt8c0n7ls2nmcur7di87b